RDHL

Movantik® (naloxegol)

Opioid-induced constipation (OIC)

Quarterly Sales (Approved)

Exp Date

March 5, 2021 (Est)

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: Movantik® (naloxegol) in Opioid-induced constipation (OIC)- Quarterly Sales


WHAT IS THE CATALYST EVENT?

  • Quarterly sales


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • March 5, 2021 (Est)


PRIOR DATA/EVENTS

PRESS RELEASE


Quarter's sales: $21M (Q3/2020)

2020 Revenue guidance: NOT PROVIDED by company

PUBLICATION

MECHANISM OF ACTION / RATIONALE

  • Naloxegol is an antagonist of opioid binding at the mu-opioid receptor. When administered at the recommended dose levels, naloxegol functions as a peripherally-acting mu-opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids. Naloxegol is a PEGylated derivative of naloxone, and is a substrate for the P-glycoprotein transporter (P-gp). Also, the presence of the PEG moiety in naloxegol reduces its passive permeability as compared with naloxone. Due to the reduced permeability and increased efflux of naloxegol across the blood-brain barrier, related to P-gp substrate properties, the CNS penetration of naloxegol is expected to be negligible at the recommended dose levels limiting the potential for interference with centrally mediated opioid analgesia (Learn more HERE). 

Updated by HC

#RDHL, #Movantik, #naloxegol, #Opioid-induced constipation, #OIC, #constipation, #opioid, #chronic pain, #pain, #opioids

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

RDHL - RedHill Biopharma Provi...

Summary: Q3/2020 net revenues of approximately $21 million, with gross profit of $10.6 million, or approximately 51%, up from $6.7 million and approximately 32% in Q2/2020 Strong growth for Talicia® w...

RDHL - Positive Recommendation...

#RDHL announced that its U.S. Phase 2 study with #opaganib (#Yeliva®, #ABC294640)1 in patients hospitalized with severe #COVID-19 pneumonia, has successfully passed the first scheduled independent Saf...

RDHL - Opaganib COVID-19 Study...

#RDHL announced that the "U.S. Phase 2 study with opaganib (Yeliva®, ABC294640)1 in patients hospitalized with severe COVID-19 pneumonia has passed its second pre-scheduled safety review by the indepe...

RDHL - Brazil Approves RedHill...

#RDHL announced "approval from the Brazilian Health Regulatory Agency (ANVISA) for its ongoing global Phase 2/3 study evaluating opaganib1 in patients hospitalized with severe COVID-19 pneumonia. Opag...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon